AKSHIT M. RAYCHA HUF has filed a formal disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the acquisition of additional equity shares in Achyut Healthcare Limited through open market purchase on March 12, 2026. The regulatory filing was submitted to the BSE Limited's Listing Compliance Department.

Acquisition Details

The transaction involved the purchase of 10,985 equity shares through open market operations, representing a marginal increase in the promoter group entity's shareholding. The acquisition increased AKSHIT M. RAYCHA HUF's total shareholding from 4,538,520 shares to 4,549,505 shares.

Regulatory Compliance Framework

The disclosure was made in accordance with SEBI regulations governing substantial acquisition of shares. AKSHIT M. RAYCHA HUF, identified as belonging to the promoter group of Achyut Healthcare Limited, submitted the required documentation to fulfill regulatory compliance obligations. The entity maintains no encumbrances, pledges, or liens on the acquired shares.

Company Capital Structure

Achyut Healthcare Limited's equity structure remains unchanged following this transaction. The company maintains its listing on the Bombay Stock Exchange Limited with a stable capital base.

Transaction Documentation

The formal disclosure letter was submitted by AKSHIT M. RAYCHA HUF from their registered address in Ahmedabad to the BSE's Listing Compliance Department. The filing included detailed annexures as per the prescribed format under SEBI regulations, covering all aspects of the share acquisition including pre and post-acquisition holdings, voting rights, and transaction specifics.

No warrants, convertible securities, or other instruments entitling voting rights were involved in this transaction. The acquisition represents a routine increase in promoter group shareholding through standard market operations, with all regulatory requirements being duly fulfilled.

Achyut Healthcare Limited has received in-principle approval from BSE Limited for a preferential issue of equity shares, marking a significant step in the company's capital raising initiative. The approval was communicated through BSE's letter dated March 11, 2026, and subsequently disclosed by the company on March 12, 2026.

Preferential Issue Details

The BSE has granted approval for the issuance of substantial equity shares under specific terms and conditions:

Regulatory Compliance Requirements

BSE has outlined comprehensive compliance requirements that the company must fulfill before proceeding with the allotment. The approval is subject to strict adherence to multiple regulatory frameworks including:

• Companies Act, 2013
• Securities Contracts (Regulation) Act, 1956
• Securities and Exchange Board of India Act, 1992
• Depositories Act, 1996
• SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018
• SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Key Compliance Measures

The exchange has mandated specific internal control measures to ensure regulatory compliance:

• Trading Restrictions: The company must obtain undertakings from allottees confirming they will not engage in intra-day trading or sell shares until the allotment date
• Verification Responsibility: Complete onus lies on the issuer company to verify compliance with SEBI ICDR Regulations, particularly Regulation 167(6)
• Listing Timeline: Application for listing must be made within twenty days from the date of allotment as per SEBI circular dated June 21, 2023

Post-Allotment Obligations

Upon completion of the allotment, Achyut Healthcare Limited will be required to submit a listing application with applicable fees under Regulation 14 of LODR Regulations. The company must also complete all post-issue formalities as specified by the exchange.

Important Disclaimers

BSE has clarified that this in-principle approval should not be construed as approval for listing of the securities. The exchange reserves the right to withdraw approval if any information is found to be incomplete, incorrect, misleading, or in contravention of applicable regulations. Any non-compliance with the twenty-day listing application requirement will attract penalties as specified in the relevant SEBI circular.